×

CORRECTED-Chinese firms among bidders for Australia's I-MED, valued at over $765 mln-sources

$765 mln-sources@ (Corrects alert and headline to say $765 mln, not $765 bln)

* Tonghua Golden-Horse, Golden Meditech among bidders -sources

* Ontario Teachers', Permira also to bid -sources

* Binding bids due by end of this month

* Deal to value I-MED around 10-12 times its 2017 EBITDA

HONG KONG/SYDNEY, Nov 1 (Reuters) - Two Chinese healthcare firms are among investors seeking to buy Australia's I-MED Radiology Network in a deal that could value the X-ray provider at more than A$1 billion ($765 million), people with knowledge of the matter said.

Shenzhen-listed Tonghua Golden-Horse Pharmaceutical Industry and Hong Kong-listed Golden Meditech Holdings , are likely to participate in a second round of bidding, three people told Reuters.

The Ontario Teachers' Pension Plan, Canada's third-largest public pension plan, and London-based private equity firm Permira, are also expected to submit separate bids, two of the people said.

Binding bids are due by end of this month.

Chinese interest in Australia's biggest X-ray provider comes as Beijing strives to overhaul its healthcare sector and boost the competitiveness of the domestic industry in overseas markets, with acquisitions one of the key planks for that drive.

With nearly 200 clinics cross Australia, I-MED has 18 percent of the nation's diagnostic imaging services market, which is partially subsidised by the government, according to a September report by researcher IBISWorld.

I-MED's owner, Swedish private equity firm EQT Holdings, has hired Morgan Stanley and Rothschild to manage the sale process, the people said, who declined to be identified as the deal process is not public.

Representatives from Tonghua Golden-Horse, Golden Meditech, I-MED, Ontario Teachers Pension Plan and Rothschild did not respond to Reuters requests for comment. EQT, Morgan Stanley and Permira declined to comment.

I-MED booked A$608 million in sales and A$100 million in earnings before interest, tax, depreciation and amortization (EBITDA) in its 2016 financial year, according to EQT's website. (Reporting by Carol Zhong of Basis Point, Julie Zhu in Hong Kong and Paulina Duran in Sydney; Additional reporting by Kane Wu in Hong Kong; Editing by Sumeet Chatterjee and Edwina Gibbs)